至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

Nat Med. 2021-01; 
Zhuting Hu, Donna E Leet, Rosa L Allesøe, Giacomo Oliveira, Shuqiang Li, Adrienne M Luoma, Jinyan Liu, Juliet Forman, Teddy Huang, J Bryan Iorgulescu, Rebecca Holden, Siranush Sarkizova, Satyen H Gohil, Robert A Redd, Jing Sun, Liudmila Elagina, Anita Giobbie-Hurder, Wandi Zhang, Lauren Peter, Zoe Ciantra, Scott Rodig, Oriol Olive, Keerthi Shetty, Jason Pyrdol, Mohamed Uduman, Patrick C Lee, Pavan Bachireddy, Elizabeth I Buchbinder, Charles H Yoon, Donna Neuberg, Bradley L Pentelute, Nir Hacohen, Kenneth J Livak, Sachet A Shukla, Lars Rønn Olsen, Dan H Barouch, Kai W Wucherpfennig, Edward F Fritsch, Derin B Keskin, Catherine J Wu, Patrick A Ott
Products/Services Used Details Operation
Neoantigen Peptide Service T cells were co-cultured with an equal number of patient-derived B cells immortalized with the EBV virus (EBV lymphoblastoid cell lines, EBV-LCL) and pulsed with different doses of mutated or wildtype neoantigen peptides (Genscript). Get A Quote

摘要

Personal neoantigen vaccines have been envisioned as an effective approach to induce, amplify and diversify antitumor T cell responses. To define the long-term effects of such a vaccine, we evaluated the clinical outcome and circulating immune responses of eight patients with surgically resected stage IIIB/C or IVM1a/b melanoma, at a median of almost 4 years after treatment with NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient ( NCT01970358 ). All patients were alive and six were without evidence of active disease. We observed long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a m... More

关键词